Appetite suppressants as agonist substitution therapies for stimulant dependence

Annals of the New York Academy of Sciences

Volumn 965, Issue , 2002, Pages 109-126

  Rothman, Richard B ^a   Blough, Bruce E ^b   Baumann, Michael H ^a  

^a NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

^b RTI INTERNATIONAL   (United States)

Author keywords

Agonist substitution therapy; Appetite suppressant; Dual deficit model; Methamphetamine; Stimulant withdrawal

Indexed keywords

AMFEPRAMONE; AMINOREX; AMPHETAMINE DERIVATIVE; ANOREXIGENIC AGENT; BRAIN MONOAMINE; CHLORPHENTERMINE; DOPAMINE; EPHEDRINE; FENFLURAMINE; METHAMPHETAMINE; PHENTERMINE; PSYCHOSTIMULANT AGENT; SEROTONIN;

ANHEDONIA; ANIMAL EXPERIMENT; ANIMAL MODEL; BRAIN DYSFUNCTION; COCAINE DEPENDENCE; CONFERENCE PAPER; DEPRESSION; DOSE RESPONSE; DRIVE; DRUG DEPENDENCE; DRUG EFFECT; MALE; NEUROTRANSMITTER RELEASE; NONHUMAN; NUCLEUS ACCUMBENS; OBSESSION; PSYCHOMOTOR DISORDER; RAT; RELAPSE; WITHDRAWAL SYNDROME;

ANIMALIA;

EID: 0036296867     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2002.tb04155.x     Document Type: Conference Paper

References (80)

1. Cocaine and methamphetamine: Differential addiction rates
2. Cocaine's history, especially the American experience
3. Cocaine abuse in North America: A milestone in history
4. Increasing morbidity and mortality associated with abuse of methamphetamine - United States, 1991-1994
5. Psychiatric comorbidity of methamphetamine dependence in a forensic sample
6. Comorbidity of mental disorders with alcohol and other drug abuse
7. Prevalence and treatment models for addiction in psychiatric populations
8. A double epidemic: Crystal methamphetamine drug use in relation to HIV transmission among gay men
9. Drug abuse, psychiatric disorders, and AIDS. Dual and triple diagnosis
10. Research and development costs for new drugs by therapeutic category. A study of the US pharmaceutical industry
11. Overview: Medications development for the treatment of drug abuse
12. The rate hypothesis and agonist substitution approaches to cocaine abuse treatment
13. Nicotine medications for smoking cessation
14. Opiates, opioids and addiction
15. Substitution pharmacotherapies for opioid addiction: From methadone to LAAM and buprenorphine
16. Replacement medication for cocaine dependence: Methylphenidate
17. Dextroamphetamine for cocaine-dependence treatment: A double-blind randomized clinical trial
18. The combination of phentermine and fenfluramine reduced cocaine withdrawal symptoms in an open trial
19. Modulation of intravenous cocaine effects by chronic oral cocaine in humans
20. Diethylpropion pharmacotherapeutic adjuvant therapy for inpatient treatment of cocaine dependence: A test of the cocaine-agonist hypothesis
21. Pharmacological approaches to cocaine addiction
22. Central stimulant abuse: Neurochemistry and pharmacotherapy
23. Pharmacologic therapies for cocaine and other stimulant addiction
24. Variability in treatment-seeking cocaine abusers: Implications for clincal pharmacotherapy trials
25. Neurochemical changes in cocaine withdrawal
26. Neurochemical correlates of cocaine and ethanol self-administration
27. Chronic cocaine enhances serotonin autoregulation and serotonin uptake binding
28. Serotonin dysfunction in the nucleus accumbens of rats during withdrawal after unlimited access to intravenous cocaine
29. Evidence for alterations in presynaptic serotonergic function during withdrawal from chronic cocaine in rats
30. Serotonergic dysfunction during cocaine withdrawal: Implications for cocaine-induced depression
31. Monoaminergic regulation of neuroendocrine function and its modification by cocaine
32. The effect of chronic cocaine on basal extracellular dopamine in the nucleus accumbens
33. Apparent synaptic dopamine deficiency induced by withdrawal from chronic cocaine treatment
34. Marked inhibition of mesolimbic dopamine release: A common feature of ethanol, morphine, cocaine and amphetamine abstinence in rats
35. Phentermine and fenfluramine: Preclinical studies in animal models of cocaine addiction
36. Alterations in serotonergic responsiveness during cocaine withdrawal in rats: Similarities to major depression in humans
37. Effects of phentermine and fenfluramine on extracellular dopamine and serotonin in rat nucleus accumbens: Therapeutic implications
38. Differential effects of withdrawal from chronic amphetamine or fluoxetine administration on brain stimulation reward in the rat - Interactions between the two drugs
39. Postcocaine anhedonia. An animal model of cocaine withdrawal
40. Amphetamine and fenfluramine suppress ethanol intake in ethanol-dependent rats
41. Differential effects of monoaminergic agonists on alcohol intake in rats fed a tryptophan-enhanced diet
42. Combined dopamine and serotonin agonists: A synergistic approach to alcoholism and other addictive behaviors
43. Combined use of fenfluramine and phentermine in the treatment of cocaine addiction: A pilot case series
44. Comparison of behavior maintained by infusions of eight phenylethylamines in baboons
45. Anorectics: Effects on food intake and self-administration in rhesus monkeys
46. Amphetamine-like effects of anorectics and related compounds in pigeons
47. Substitution and cross-tolerance profiles of anorectic drugs in rats trained to detect the discriminative stimulus properties of cocaine
48. Behavioural and neurochemical characteristics of phentermine and fenfluramine administered separately and as a mixture in rats
49. Effects of fenfluramine and phentermine (fenphen) on dopamine and serotonin release in rat striatum: In vivo microdialysis study in conscious animals
50. Aminorex, fenfluramine, and chlorphentermine are serotonin transporter substrates: Implications for primary pulmonary hypertension
51. Evaluation of phentermine and fenfluramine, alone and in combination, in normal, healthy volunteers
52. Inhibition of cocaine self-administration by fluoxetine or D-fenfluramine combined with phentermine
53. Drug self-administration viewed as ingestive behaviour
54. Chronic food deprivation decreases extracellular dopamine in the nucleus accumbens: Implications for a possible neurochemical link between weight loss and drug abuse
55. Feeding, drug abuse, and the sensitization of reward by metabolic need
56. Neurochemical mechanisms of phentermine and fenfluramine: Therapeutic and adverse effects
57. Effects of phentermine on responding maintained under multiple fixed-ratio schedules of food-presentation and cocaine-delivery in the rhesus monkey
58. Phentermine/fenfluramine decreases cocaine self-administration in rhesus monkeys
59. Effects of dopamine and serotonin-releasing agents on methamphetamine discrimination and self-administration in rats
60. A comparison of cocaine, GBR 12909, and phentermine self-administration by rhesus monkeys on a progressive-ratio schedule
61. From synapse to vesicle: The reuptake and storage of biogenic amine neurotransmitters
62. Neurotransmitter transporters as molecular targets for addictive drugs
63. GBR12909 attenuates cocaine-induced activation of mesolimbic dopamine neurons in the rat
64. Hippocampus norepinephrine, caudate dopamine and serotonin, and behavioral responses to the stereoisomers of amphetamine and methamphetamine
65. Pharmacokinetic and pharmacodynamic analysis of the actions of D-amphetamine and D-methamphetamine on the dopamine terminal
66. Inhibition of MAO-A fails to alter cocaine-induced increases in extracellular dopamine and norepinephrine in rat nucleus accumbens
67. Neurochemical neutralization of methamphetamine with high affinity non-selective inhibitors of biogenic amine transporters: A pharmacological strategy for treating stimulant abuse
68. 125I]RTI-55 in membranes prepared from human, monkey and guinea pig caudate
69. Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin
70. A simple apparatus for studying the release of neurotransmitters from synaptosomes
71. Carrier-dependent and Ca(2+)-dependent 5-HT and dopamine release induced by (+)-amphetamine, 3,4-methylendioxymethamphetamine, p-chloroamphetamine and (+)-fenfluramine
72. In vitro studies on the mechanism by which (+)-norfenfluramine induces serotonin and dopamine release from the vesicular storage pool
73. Uptake and release effects of diethylpropion and its metabolites with biogenic amine transporters
74. Simultaneous determination of amfepramon and its two major metabolites in biological fluids by gas liquid chromatography
75. Bioavailability in man of phendimetrazine from various dosage forms
76. Valvular heart disease associated with fenfluramine-phentermine
77. Obesity drugs and the heart
78. Aminorex pulmonary hypertension
79. Assessment of reinforcing properties of amphetamine analogues in self-administering rats